The Steubenville Top 5

[mrmarket]

Here are my five favorite stocks for this week....will buy one of these soon...which one do YOU like?

ANIK CBZ DXPE SHLO TARO

[mimo_100]

I still like ANIK from the previous dump.

[billyjoe]

I analyzed the top 5 using 14 variables on a 1-5 scale 1 being the best. So the lowest average score should be the winner.

1. SHLO--2.286

2. ANIK--2.786

3. CBZ---2.929

4. DXPE--3.143

5. TARO--3.357

Not too scientific since I gave equal value to all parameters, earnings, p/e, sales, ROA, institutional ownership, volume, RT etc.

----------------billy

[drutzen]

Well, since I jumped the gun the last time, let's go with ANIK, I still own it

[mimo_100]

SYMBOL    SHARES    TRD DATE    PRICE PAID    PRICE    MKT VALUE    GAIN & % GAIN    NAME    
ANIK        12/17/2013    33.69    35.69    $35.69    $+2.00    5.94%    Anika Therapeutics Inc.
                                
CBZ        12/17/2013    8.97       8.99        8.99      $+0.02    0.22%    CBIZ, Inc.
                                
DXPE        12/17/2013    106.29    108.54    $108.54    $+2.25    2.12%    DXP Enterprises, Inc.
                                
SHLO        12/17/2013    21.77    20.64    $20.64    $-1.13    -5.19%    Shiloh Industries Inc.
                                
TARO    12/17/2013    94.3            94.44    $94.44    $+0.14    0.15%    Taro Pharmaceutical Industries Ltd.

[sixfeetfour]

SHLO nearly jumped 15% in one day after their earning report

Sales revenue for the quarter was $206.6 million and improved 38.8 percent from the fourth quarter a year earlier. Fiscal 2013 sales revenues reached a record $700.2 million, a 19.5 percent improvement over the prior year.

Gross profit for the quarter improved over 76 percent from the fourth quarter a year earlier and was $22.1 million, or 10.7 percent of sales revenue. Fiscal 2013 gross profit was $71.7 million or 10.2 percent of sales revenue and improved over 41 percent over the prior year.

Operating income for the quarter improved 48 percent to $10.8 million, from the fourth quarter a year earlier. Fiscal 2013 operating income was $34.6 million and improved 44 percent over the prior year.

Will MM jump on the train? I think MM will go with TARO, it ranks the highest (10 on Hagstrom, Weiss, Scouter, IBD check-up. At least when I ran the numbers yesterday night.